CN115811984A - 抗病毒的结构上稳定的SARS-CoV-2肽和其用途 - Google Patents

抗病毒的结构上稳定的SARS-CoV-2肽和其用途 Download PDF

Info

Publication number
CN115811984A
CN115811984A CN202180032678.6A CN202180032678A CN115811984A CN 115811984 A CN115811984 A CN 115811984A CN 202180032678 A CN202180032678 A CN 202180032678A CN 115811984 A CN115811984 A CN 115811984A
Authority
CN
China
Prior art keywords
seq
xaa
amino acid
independently
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180032678.6A
Other languages
English (en)
Chinese (zh)
Inventor
L·D·瓦伦斯基
G·H·博德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN115811984A publication Critical patent/CN115811984A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202180032678.6A 2020-03-04 2021-03-04 抗病毒的结构上稳定的SARS-CoV-2肽和其用途 Pending CN115811984A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985100P 2020-03-04 2020-03-04
US62/985,100 2020-03-04
PCT/US2021/020940 WO2021178714A2 (en) 2020-03-04 2021-03-04 ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN115811984A true CN115811984A (zh) 2023-03-17

Family

ID=75223491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032678.6A Pending CN115811984A (zh) 2020-03-04 2021-03-04 抗病毒的结构上稳定的SARS-CoV-2肽和其用途

Country Status (8)

Country Link
US (1) US20240124529A1 (enExample)
EP (1) EP4114431A2 (enExample)
JP (1) JP2023517293A (enExample)
KR (1) KR20220148869A (enExample)
CN (1) CN115811984A (enExample)
AU (1) AU2021230544A1 (enExample)
CA (1) CA3173973A1 (enExample)
WO (1) WO2021178714A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297498A (en) * 2020-04-24 2022-12-01 Univ Columbia Lipid-peptide fusion inhibitors as sars-cov-2 antivirals
CN113817026B (zh) * 2021-09-16 2023-06-30 中国人民解放军海军军医大学 靶向刺突蛋白hr1的订书肽、制备方法及抗新型冠状病毒应用
CN113773370B (zh) * 2021-10-15 2022-07-22 哈尔滨吉象隆生物技术有限公司 一种抗病毒的多肽及其应用
CN118354791A (zh) * 2021-10-22 2024-07-16 威斯康星校友研究基金会 抑制导致新冠肺炎疾病的病毒sars-cov-2感染的肽
CN114437196A (zh) * 2022-02-16 2022-05-06 复旦大学 一种抑制SARS-CoV-2感染的蛋白及其用途
EP4611789A1 (en) * 2022-11-06 2025-09-10 Leyden Laboratories B.V. Sars-cov-2 binding polypeptide
EP4676938A2 (en) * 2023-03-08 2026-01-14 Dana-Farber Cancer Institute, Inc. Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
WO2025235945A1 (en) * 2024-05-10 2025-11-13 Red Queen Therapeutics, Inc. Methods of treating viral infections using a fusion inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
PT1053019E (pt) 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
WO2005077103A2 (en) * 2004-02-12 2005-08-25 Regents Of The University Of Colorado Compositions and methods for modification and prevention of sars coronavirus infectivity
US7491489B2 (en) * 2004-11-22 2009-02-17 The University Of Hong Knog Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
WO2007005249A2 (en) * 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) * 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
WO2009137532A1 (en) * 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
US9175047B2 (en) * 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2010263056B2 (en) * 2009-06-18 2016-01-07 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
CN102939101A (zh) * 2010-01-26 2013-02-20 科罗拉多大学董事会，法人 用于通用疫苗的流感病毒组合物和方法
GB2473525B (en) * 2010-07-19 2011-07-27 Alexander P Fisher System and method for growing plants
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
CN107022008B (zh) * 2016-01-30 2021-04-23 山西锦波生物医药股份有限公司 广谱地抑制人类冠状病毒感染的多肽及其应用
US20190048038A1 (en) 2016-02-23 2019-02-14 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
WO2019136824A1 (zh) * 2018-01-15 2019-07-18 中国人民解放军军事科学院军事医学研究院 抑制MERS-CoV感染的多肽

Also Published As

Publication number Publication date
JP2023517293A (ja) 2023-04-25
WO2021178714A3 (en) 2022-02-17
WO2021178714A2 (en) 2021-09-10
EP4114431A2 (en) 2023-01-11
US20240124529A1 (en) 2024-04-18
KR20220148869A (ko) 2022-11-07
CA3173973A1 (en) 2021-09-10
AU2021230544A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN115811984A (zh) 抗病毒的结构上稳定的SARS-CoV-2肽和其用途
CA2862391C (en) Stabilized antiviral fusion helices
US20250084128A1 (en) ANTIVIRAL STRUCTURALLY-STAPLED SARS-CoV-2 PEPTIDE-CHOLESTEROL CONJUGATES AND USES THEREOF
AU2021258205A1 (en) Antiviral structurally-stabilized ACE2 helix 1 peptides and uses thereof
KR20230170918A (ko) 펩티드 및 펩티드를 포함하는 조성물
JP7854211B2 (ja) ヘマグルチニン結合ペプチド
US20260041753A1 (en) Respiratory syncytial virus surface glycoprotein peptides, conjugates, and uses thereof
US20240052330A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
EP4676938A2 (en) Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
US20250288658A1 (en) Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
CN117858889A (zh) 肽及包含肽的组合物
CN117677628A (zh) Ghr结合未决肽及包含所述肽的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination